- Five Ways to Explore NASA’s Portfolio of Technologies with TechPort 4.0
- Alphemy Capital appoints Barry Schachter as Head of Portfolio Risk Management
- Dogecoin Faces 14% Drop: Key Levels for Future Recovery
- Lazard Enhanced Opportunities Portfolio Q3 2024 Commentary (Mutual Fund:LEOIX)
- Suntex Adds Another California Marina to Portfolio
Amedisys’ AMED growth in the third quarter of 2024 was driven by its continuously improving clinical quality for patients, demonstrated through high Quality of Patient Care and Patient Satisfaction star ratings. The company’s anticipated merger with UnitedHealth Group’s Optum is expected to generate significant synergies. However, a dull macroeconomic scenario and fierce competitive pressure may restrict Amedisys’ growth potential.
Bạn đang xem: Reasons to Retain AMED Stock in Your Portfolio Now
In the past year, this Zacks Rank #3 (Hold) company’s shares have lost 4.3% against the industry’s 9.6% growth and the S&P 500 composite’s 25.8% increase.
The leading home health and hospice services provider has a market capitalization of $2.95 billion. Amedisys has an earnings yield of 4.9%, much higher than the industry’s 4.1%.
Selloff Decision, A Strategic Pact: In June 2023, Amedisys announced that it received an unsolicited proposal from UnitedHealth Group’s Optum — a diversified health services company — to acquire all of the outstanding shares of Amedisys’ common stock in an all-cash transaction for $101 per share. Combining Optum’s extensive value-based care knowledge with Amedisys’ dedication to quality and care innovation in the home and its employees’ patient-first culture can significantly enhance the health outcomes and experiences of more patients at lower costs, resulting in continuous growth.
Efforts to Improve Clinical Quality: Amedisys’ focus on clinical distinction is demonstrated through its Quality of Patient Care and Patient Satisfaction star ratings. In the Centers for Medicare and Medicaid Services’ reports for the October 2024 Final release, the Quality of Patient Care star average across all Amedisys providers was 4.24, with 89% of its care centers at 4+ Stars and 56% at 4.5+ Stars. Amedisys’ Patient Satisfaction star average for the October 2024 release was 3.78, outperforming the industry. The company aims to achieve a 4.0 Quality of Patient Care star rating for all its care centers. It has implemented targeted action plans to continue to improve the quality of care for patients and further its culture of quality.
Macroeconomic Pressure on Business Operations: With escalating conflicts in the Middle East, Ukraine and other geopolitical tensions creating volatility in the global financial markets, these issues are likely to cause severe disruptions in the global supply chain and energy markets.
Xem thêm : DGeo Expands Sustainable Packaging Portfolio With Lifoam’s BioEPS Products
Image Source: Zacks Investment Research
Furthermore, inflation has increased steadily throughout the United States. Amedisys anticipates these pressures to persist throughout 2024. As a recent example, the company reported a $43.3 million increase in general and administrative expenses in the third quarter of 2024. This was largely due to planned wage increases, higher health insurance costs, and increased legal and IT-related expenditures.
Nguồn: https://earnestmoney.skin
Danh mục: News